U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06895993) titled 'Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants' on March 20.
Brief Summary: The goal of this clinical trial is to compare the pharmacokinetic profile of the developed drug product and reference product in healthy participants under fasting condition. The main questions it aims to answer are:
* [Question 1] Is there significant difference in the pharmacokinetic profile between the ferric carboxymaltose injection (100 mg iron/2 mL) provided by Sichuan Huiyu Pharmaceutical Co., Ltd. and the ferric carboxymaltose injection licensed by American Regent, Inc. (trade name: Injectafer(R), strength: ...